BR112017023351A2 - composições multidrogas de matriz frágil - Google Patents

composições multidrogas de matriz frágil

Info

Publication number
BR112017023351A2
BR112017023351A2 BR112017023351A BR112017023351A BR112017023351A2 BR 112017023351 A2 BR112017023351 A2 BR 112017023351A2 BR 112017023351 A BR112017023351 A BR 112017023351A BR 112017023351 A BR112017023351 A BR 112017023351A BR 112017023351 A2 BR112017023351 A2 BR 112017023351A2
Authority
BR
Brazil
Prior art keywords
compositions
multidrug
drug combinations
fragile matrix
fragile
Prior art date
Application number
BR112017023351A
Other languages
English (en)
Other versions
BR112017023351B1 (pt
Inventor
Watts Alan
Peters Jay
Williams Robert
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112017023351A2 publication Critical patent/BR112017023351A2/pt
Publication of BR112017023351B1 publication Critical patent/BR112017023351B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a invenção diz respeito a combinações de medicamento duplo e triplo de fármacos formulados como partículas de matriz quebradiças com uma área de superfície elevada são providas neste documento. estas formulações de partículas podem ser utilizadas em técnicas de inalação ou de administração de aerossóis para prover as combinações de fármacos aos pulmões. em alguns aspectos, essas composições podem ser usadas para tratar uma doença ou distúrbio respiratório, como asma ou copd.
BR112017023351-7A 2015-05-01 2015-09-02 Composição farmacêutica e uso da composição farmacêutica BR112017023351B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156052P 2015-05-01 2015-05-01
US62/156,052 2015-05-01
PCT/US2015/048093 WO2016178704A1 (en) 2015-05-01 2015-09-02 Multidrug brittle matrix compositions

Publications (2)

Publication Number Publication Date
BR112017023351A2 true BR112017023351A2 (pt) 2018-07-17
BR112017023351B1 BR112017023351B1 (pt) 2023-11-28

Family

ID=54147283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023351-7A BR112017023351B1 (pt) 2015-05-01 2015-09-02 Composição farmacêutica e uso da composição farmacêutica

Country Status (9)

Country Link
US (1) US20180147161A1 (pt)
EP (1) EP3288541B1 (pt)
JP (3) JP6940416B2 (pt)
KR (1) KR102356120B1 (pt)
CN (1) CN107666903B (pt)
AU (2) AU2015393953B2 (pt)
BR (1) BR112017023351B1 (pt)
CA (1) CA2983427C (pt)
WO (1) WO2016178704A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
MX2021000796A (es) * 2018-07-24 2021-06-15 Univ Texas Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida.
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
CN115267024B (zh) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 治疗呼吸系统疾病的药物组合物及其检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723314C (en) * 2008-02-13 2017-01-10 The Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
BRPI0915803A2 (pt) * 2008-07-18 2015-11-10 Prosonix Ltd processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador
US20120083531A1 (en) * 2009-03-26 2012-04-05 Clarke Robert W Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP2498903A4 (en) * 2009-11-09 2013-10-30 Univ Texas METHOD USING EMULSION MATRIX FOR FORMING SMALL PARTICLES OF HYDROPHOBIC AGENTS WITH SURFACE ENRICHED HYDROPHILIC CHARACTER BY ULTRA FAST FREEZING
CN102811715A (zh) * 2009-12-08 2012-12-05 悉尼大学 可吸入制剂
KR20180028563A (ko) * 2010-10-12 2018-03-16 시플라 리미티드 약학 조성물
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
US20150136130A1 (en) * 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
WO2014007770A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
EA029125B1 (ru) * 2013-07-11 2018-02-28 Кьези Фармасьютичи С.П.А. Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции

Also Published As

Publication number Publication date
WO2016178704A1 (en) 2016-11-10
AU2021277656B2 (en) 2023-11-09
AU2015393953B2 (en) 2021-09-02
JP2018514569A (ja) 2018-06-07
KR20180003572A (ko) 2018-01-09
JP2021080298A (ja) 2021-05-27
US20180147161A1 (en) 2018-05-31
BR112017023351B1 (pt) 2023-11-28
AU2021277656A1 (en) 2021-12-23
CN107666903B (zh) 2021-08-20
JP2022069565A (ja) 2022-05-11
CN107666903A (zh) 2018-02-06
EP3288541B1 (en) 2020-09-02
JP6940416B2 (ja) 2021-09-29
AU2015393953A1 (en) 2017-11-09
CA2983427C (en) 2024-04-23
EP3288541A1 (en) 2018-03-07
CA2983427A1 (en) 2016-11-10
KR102356120B1 (ko) 2022-01-28

Similar Documents

Publication Publication Date Title
BR112017023351A2 (pt) composições multidrogas de matriz frágil
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016500094A1 (en) Autotaxin inhibitors
IL246117A0 (en) Administration, use and therapeutic applications of crispr-cas systems and preparations for HBV and viral diseases and disorders
IL243195A0 (en) Provision, use and therapeutic applications of crisps-cas systems and preparations aimed at disorders and diseases using viral components
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
MD3500241T2 (ro) Terapie combinată pentru BPOC
EA201892327A1 (ru) Ингаляционные и назальные бензодиазепины
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
PL3369429T3 (pl) Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa
EP2682103A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
TR200907913A2 (tr) İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
TR201712424A2 (tr) Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
PH12015501313B1 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2015, OBSERVADAS AS CONDICOES LEGAIS